RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Regenerative Medicine Advanced Therapy (United States), Conditional marketing approval (Australia), Priority Review (United States)

Clinical Trials associated with Lifileucel

NCT07700121

/ Not yet recruitingEarly Phase 1IIT

PICSTAT (PET Imaging of CD8 for Selection of Tumors for Autologous TIL): A Pilot Study Assessing the Use of CD8 PET/CT (Zr-89 Crefmirlimab Berdoxam) to Enhance Lifileucel (AMTAGVI) Efficacy in Patients With Treatment Refractory Stage IV Melanoma

This prospective, single-center pilot study is being performed to find out whether Zr-89 crefmirlimab berdoxam "CD8 PET/CT" scans can improve the effectiveness of the tumor-infiltrating lymphocyte (TIL) therapy called lifileucel ("Study Treatment") in treating metastatic melanoma.
Participants must first provide consent to the companion protocol (UPCC 19426, PICSTAT CD8 PET) before being eligible to consent to this protocol.

Start Date01 Oct 2026

Sponsor / Collaborator

Abramson Cancer Center

[+1]

NCT07741877

/ Not yet recruitingPhase 2

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Soft Tissue Sarcoma

A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')

Start Date01 Sep 2026

Sponsor / Collaborator

Iovance Biotherapeutics, Inc.

NCT07288073

/ RecruitingPhase 2IIT

A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma

The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with Cutaneous squamous cell carcinoma (CSCC) or Merkel Cell Carcinoma (MCC) who were previously treated with immunotherapy.
The names of the study interventions involved in this study are:
* Tumor Infiltrating Lymphocytes (a type of cellular therapy)
* Fludarabine and Cyclophosphamide (types of standard of care chemotherapy drugs)
* Interleukin-2 (a type of recombinant, human glycoprotein)

Start Date10 Feb 2026

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

100 Clinical Results associated with Lifileucel

100 Translational Medicine associated with Lifileucel

100 Patents (Medical) associated with Lifileucel

Literatures (Medical) associated with Lifileucel

16 Jun 2026·CURRENT CANCER DRUG TARGETS

Transformative Advances in the Treatment of Melanoma: A Review

Article

Author: Tyagi, Rama ; Sharma, Vikram ; Khosla, Gayatri ; Yeole, Kalpesh ; Wadekar, Raju

Recent advancements in melanoma treatment have reinvigorated hope among patients, significantly shifting the therapeutic landscape. A significant advancement in patient outcomes has been realised by applying first-line treatment strategies that include Immune Checkpoint Inhibitors (ICIs) and targeted therapies. Ipilimumab combined with nivolumab has demonstrated superior outcomes, earning a median overall survival surpassing 70 months. This notable success signifies a pivotal shift in the management of advanced melanoma, reflecting effective therapeutic strategies that clinicians can leverage. The advent of new ICIs, such as relatlimab, introduces additional complexities in decision-making for first-line therapy. Understanding the nuances of various treatments will empower physicians to make informed decisions. Several important characteristics, including brain metastases, PD-L1 expression, BRAF mutation status, performance status, and any previous adjuvant treatments, influence the treatment of advanced melanoma. These factors influence the choice of therapy and the potential efficacy in individual cases, underscoring the need for personalised treatment approaches. This review also sheds light on rare melanoma subtypes, particularly uveal melanoma. The FDA approval of tebentafusp and lifileucel has demonstrated potential in extending the survival time of patients with metastatic uveal melanoma. This progress highlights the importance of innovative therapies tailored to unique cancer profiles. By providing recent insights into these evolving treatment options, this review is an invaluable resource for clinicians. It aims to facilitate informed treatment decisions and enhance understanding of the multifaceted challenges in effectively managing advanced melanoma. As new therapies emerge, continuous education and adaptability will be key to optimising patient outcomes.

05 Jun 2026·BRITISH JOURNAL OF CANCER

Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?

Review

Author: Lorigan, Paul ; Oudit, Deemesh ; Abdulgawad, Ahmed ; Lim, Kok Haw Jonathan ; Thistlethwaite, Fiona ; Woodford, Rachel

Abstract:

Tumour infiltrating lymphocyte (TIL) therapy offers the potential for durable clinical benefit in select patients with advanced melanoma, especially after progression on treatment with immune checkpoint inhibitors and/or targeted therapies. The 2024 FDA approval of Lifileucel (Amtagvi), a commercially manufactured autologous TIL product, marks a key milestone in integrating advanced therapy medicinal products (ATMPs) into routine care for solid tumours. Health Canada has since approved Lifileucel, with regulatory and funding decisions across the UK and Europe still pending. In this Perspective, we review the evidence base and outline key considerations for national adoption of TIL therapy. Despite promising results from clinical trials, TIL therapy requires complex coordination, including patient selection, tumour procurement, manufacturing logistics, lymphodepletion, and IL-2 administration; all contingent on specialised infrastructure and well-considered integrated care pathways. While commercial centralisation may ease logistical barriers, the high cost of TIL therapy necessitates careful health economic evaluation. A nationally coordinated effort is required to harmonise clinical prioritisation strategies, maintain oversight by multidisciplinary specialist tumour boards, and consider investment in future-proof decentralised manufacturing capacity. Collaborations and peer support such as through the Advanced Therapy Treatment Centre (ATTC) Network will facilitate phased, experience-led rollout with equity-focused service design.

01 Jun 2026·JAMA Dermatology

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma

Article

Author: Cornejo, Kristine ; Boland, Genevieve ; Liu, David ; LeBoeuf, Nicole R. ; Buchbinder, Elizabeth ; Sullivan, Ryan ; Sadeghi, Nakisa ; Said, Jordan T. ; Lawrence, Donald ; Haugh, Alexandra ; Semenov, Yevgeniy R. ; Cohen, Sonia ; Li, Yunxi

Importance:

Lifileucel is a first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti–programmed cell death protein 1 (PD-1) therapy and/or BRAF inhibitor therapy, if BRAF V600 mutations are present. In the C-144-01 phase 2 trial of lymphodepleting chemotherapy, lifileucel, and interleukin 2 (IL-2), cutaneous eruption occurred in 37.2% of individuals. These eruptions remain clinically and prognostically unknown.

Objective:

To examine cutaneous toxic effects development in the setting of lifileucel therapy, abstract clinical and histopathologic eruption features, and test for association with objective radiographic tumor response.

Design, Setting, and Participants:

A retrospective cohort study was performed at Mass General Brigham (MGB)/Dana-Farber Cancer Institute (DFCI) that included all patients treated with lifileucel, outside of active clinical trials. The analysis was completed in December 2025.

Exposures:

All individuals received cyclophosphamide/fludarabine lymphodepletion, lifileucel, and 6 or fewer IL-2 infusions. Demographics, melanoma-specific factors (M stage, pre-TIL lactate dehydrogenase levels, and number of lines of prior systemic therapy), number of IL-2 doses received, eruption features, photography, and dermatopathologic findings were abstracted.

Main Outcomes and Measures:

Radiographic responses 30 to 41 days, 42 to 89 days, and 90 days or longer from TIL infusion per Response Evaluation Criteria in Solid Tumors (RECIST) were abstracted. Individuals were stratified as high IL-2 (4-6 doses) or low IL-2 (1-3 doses), for objective response rate (ORR) comparison as a descriptive sensitivity analysis. An unadjusted logistic regression modeled tumor response as a binary outcome with lifileucel-associated eruption occurrence as a binary predictor. Three adjusted models included IL-2 doses (age, sex, and demographic differences) and melanoma-specific factors as covariates.

Results:

Per retrospective electronic medical health record review, among 44 individuals (34.1% female individuals; mean [SD] age, 54.8 [14.5] years), treated with lifileucel (median, 4.5 IL-2 doses), 22 (50.0%) developed an associated cutaneous eruption while hospitalized, after a median of 4 post-TIL days. Photographs from 14 of 22 individuals (63.6%) with available images demonstrated central-predominant, frequently purpuric morbilliform eruptions. ORRs did not significantly differ by IL-2 stratification (high IL-2: 50.0% vs low IL-2: 37.5%; P = .53). Cutaneous eruption development was associated with a 42-day response across analyses (analysis 1: OR, 7.29; 95% CI, 1.91-27.86; P = .004; OR, 7.65; 95% CI, 1.79-32.69; P = .006; analysis 2: OR, 11.95; 95% CI, 1.90-75.39; P = .008; analysis 3: OR, 9.73; 95% CI, 2.12-44.74; P = .003); 30-day responses were statistically similarly associated. All 90-day cutaneous eruption response analyses did not detect statistical significance.

Conclusions and Relevance:

In this cohort study, lifileucel treatment was frequently complicated by purpuric morbilliform eruptions, which were prognostically favorable and associated with short-term response. The lifileucel-associated eruption may be a peritreatment efficacy marker, assessable during the TIL treatment hospitalization prior to traditional 42-day restaging.

184

News (Medical) associated with Lifileucel

28 Jul 2026

·www.biospace.com

FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm

iStock , useng The FDA’s rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy. The FDA has deemed the single-arm mid-stage study submitted by Replimune to support the approval of an oncolytic immunotherapy “not interpretable,” setting up what should be a challenging advisory committee meeting for the biotech this week. The drug, vusolimogene oderparepvec, or RP1, has been rejected by the FDA twice . The agency accepted another resubmission in June and committed to rendering a third verdict by August 2—but also announced a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) to discuss the therapy. Two days ahead of that Thursday meeting , FDA briefing documents show that the agency still has significant concerns about the data package that Replimune has offered to support RP1’s accelerated approval in combination with Bristol Myers Squibb’s PD-1 inhibitor Opdivo for adults with unresectable advanced cutaneous melanoma who experience disease progression after a PD-1-blocking antibody-based therapy. ezstandalone.cmd.push(function () { ezstandalone.showAds(129); }); The response assessment used in the Phase 1/2 IGNYTE study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results,” the FDA reviewers said. Moreover, the agency determined that the objective response data from the single-arm trial “are not of sufficient magnitude to overcome concerns” about the drug’s efficacy. Without a reliable historical control, the FDA stated “it cannot be determined whether RP1 contributes to any observed effect” when combined with Opdivo. “The overall survival analysis from the single-arm IGNYTE study is not interpretable,” the FDA wrote. Replimune was down as much as 20% to $6.98 in premarket trading Tuesday. Replimune argued that experts have determined a randomized trial to be unethical in this population. “It is not feasible or ethical to randomize this patient population to a comparator arm of anti-PD-1 monotherapy that offered no hope for response, therefore a study comparing RP1 in combination with nivolumab, to nivolumab monotherapy in patients whose disease progressed while on nivolumab or other anti-PD-1 was not conducted,” the company wrote in its own briefing document . Replimune also addressed the FDA’s questions regarding historical data. When IGNYTE was performed, there were no treatments available for patients who had progressed after anti-PD-1 treatment, the company explained. And there is no evidence that continuing on an anti-PD-1 therapy poses any benefit to patients. “Consequently, there is very little literature evaluating this specific scenario, as continuing a therapy that has definitively failed would generally not be considered appropriate clinical practice,” Replimune wrote, adding that the IGNYTE study had strict criteria to ensure patients were “truly anti-PD-1 resistant.” Replimune also pointed out that the FDA has previously granted approval based on a single-arm study for melanoma patients. Iovance Biotherapeutics most recently received approval in 2024 for Amtagvi in this scenario. Merck’s Keytruda and Opdivo also got FDA nods for unresectable or metastatic melanoma following that of BMS’s Yervoy with single arm trials. With Replimune, however, the FDA has been consistent in its disagreement with this study design. In its first complete response letter in July 2025, the FDA said it “did not consider IGNYTE an “adequate and well-controlled clinical investigation,” a ccording to Replimune at the time. In a second CRL in April, trial design remained the sticking point for the regulator, which wrote that it “would not recommend” seeking approval based on results from a single-arm study. Complete response letters Replimune’s advanced melanoma drug rebuffed by FDA for second time The FDA in a complete response letter to Replimune maintained its original objection to the single-arm trial the biotech used to support the application for RP1. April 10, 2026 · 2 min read · Heather McKenzie Read more On Thursday, the CTGTAC will vote on just one question: Are the efficacy results from IGNYTE evaluable and clinically meaningful? Replimune’s turn before the CTGTAC will be the committee’s second event this week. On Monday, the FDA similarly released adcomm documents for Capricor’s Duchenne muscular dystrophy cell therapy deramiocel. The agency disagrees with the company’s claim that a Phase 3 trial submitted to support approval was successful. That hearing will take place Wednesday. The meetings follow a nine-month drought of adcomms at the FDA under the Trump administration. After a leadership shakeup, the agency appears to be recommitting to these public meetings. FDA FDA has recommitted to adcomms—but to what end? The FDA will hold advisory committee meetings this week for previously rejected investigational therapies from Replimune and Capricor Therapeutics. Some industry leaders were surprised the meetings were called at all, while many have questioned the rationale behind them and other adcomms on deck. July 27, 2026 · 5 min read · Michael Gibney Read more

Phase 3Cell TherapyAccelerated ApprovalDrug Approval

19 Jul 2026

·www.biospace.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 17, 2026

SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 139,930 shares of Iovance’s common stock to seventeen new, non-executive employees. The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $4.66, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics , Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi ® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. CONTACTS Investors IR@iovance.com 650-260-7120 ext. 150 Media PR@iovance.com 650-260-7120 ext. 150

Cell TherapyClinical ResultImmunotherapy

22 Jun 2026

·www.prnewswire.com

Karmanos Cancer Institute Reaches Historic Growth Milestone, Positioning Itself as a Leader in Oncology Care Delivery

Unprecedented patient demand reflects a deliberate strategy focused on access, advanced therapies and integrated research DETROIT, June 22, 2026 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren Health Care, celebrated the continued success of a multi-year growth strategy with a major milestone in FY2025, treating 15,754 new cancer cases, the most in its history. The achievement reflects a more than 47% increase in new cases compared to the 10,670 new cases in 2020, representing one of the most significant sustained growth trajectories among National Cancer Institute-Designated Comprehensive Cancer Centers nationwide. Continue Reading The Barbara Ann Karmanos Cancer Institute has seen an historic number of new cancer cases in FY25, as well as growth in cancer research, innovation and discoveries, new therapies, and more. "This phenomenal level of growth reflects the strength of our science, the compassion of our care and the growing recognition of Karmanos as a destination for comprehensive cancer treatment," said Boris Pasche, M.D., Ph.D., FACP, president and CEO of Karmanos Cancer Institute. "As we expand our reach, we are intentionally investing in leading oncologists, researchers and advanced technologies so more patients have access to innovative therapies and clinical trials that can make a meaningful difference in outcomes." Expanding Access Across the State and Beyond Headquartered in Detroit, Karmanos' 17 locations extend throughout Michigan, improving access to specialized cancer care across the region. Since 2020, several multi-million-dollar investments have added nearly 128,000 square feet of new and expanded clinical space across the Karmanos Cancer Network, serving patients across the state in areas such as Bay City, Clarkston, Flint, Lansing, Mount Pleasant, Petoskey, and Port Huron, among other cities. Karmanos completed a $48 million expansion of the Weisberg Cancer Center in Farmington Hills in 2022, and since then, it has also completed new outpatient centers in Dearborn and Roseville, as well as significant network ambulatory expansions in Clarkston, Flint and Oxford. Patients are also increasingly seeking care from Karmanos from outside Michigan, including patients from 39 states and countries. Through its Community Outreach and Engagement program, which includes Cancer Action Councils, Research and Advocacy Consortium partnerships, and lay health advisor training, Karmanos brings cancer education, screening and prevention into communities. This approach fosters trust and empowers individuals to become advocates for their health. Research and Innovation Driving National Impact Karmanos' growth is grounded in a robust research enterprise, devoting more than $60 million annually to cancer research and ensuring innovation moves seamlessly from bench to bedside. Between 2020 and October 2025, Karmanos opened 609 clinical trials and enrolled more than 2,700 patients in interventional treatment studies, giving patients their best chance against cancer through access to emerging therapies that are often unavailable elsewhere. The Institute continues to advance discoveries in tumor biology, molecular therapies and clinical trials while leading the field in innovation, including: Theranostics: An innovative approach that unites diagnosis and therapy to deliver highly personalized, targeted cancer treatment. TheraBionic P-1 device: The first FDA-approved systemic therapy using radiofrequency electromagnetic fields to treat liver cancer. Karmanos was the first cancer center in the world to offer this treatment. Lifileucel (Tumor-infiltrating Lymphocyte Therapy): Karmanos was the first cancer center in Michigan to offer this immunotherapy treatment, also known as TIL therapy, for patients with metastatic melanoma whose cancer has stopped responding to immune checkpoint inhibitors. The Gamma Knife® Icon™: A sophisticated noninvasive technology that uses radiation to destroy precisely targeted tissue to better preserve normal function. Hemgenix: Karmanos Cancer Institute was the first freestanding cancer center in the nation to provide a new gene therapy to treat hemophilia B, a rare blood-clotting disorder. Standard of care had been lifelong, often weekly, infusions to help reduce bleeding risk, but after this treatment, patients no longer must undergo them unless prepping for surgery. Recruiting Clinical Expertise That Attracts Patients and Referrals Nationally recognized clinicians and researchers play a critical role in Karmanos' continued growth. Since 2020, the Institute has reinforced its standing as one of the nation's premier cancer research and treatment organizations by recruiting 43 scientists and clinicians, strengthening its multidisciplinary teams and research leadership. Among them are Dr. Pasche, a world-renowned medical oncologist who has developed innovative new treatments for liver cancer; Wasif Saif, M.D., MBBS, a world-renowned hematologist and oncologist who now leads the Phase I Clinical Trials Multidisciplinary Team; and Azeddine Atfi, Ph.D., the new deputy center director of Research and a globally recognized molecular biologist whose pioneering research focuses on pancreatic cancer and tumor signaling pathways. Community Connection and Prevention Engages Patients Earlier Karmanos has improved its engagement with patients at critical decision points in their cancer journey through targeted education and awareness initiatives, including its Second Opinion program, which provides timely access to subspecialized expertise. These efforts help patients better understand their options and access care earlier. Karmanos' commitment to cancer prevention and early detection extends beyond its clinical walls. Annual Screening Saves Lives events help address gaps in preventive care, while community partnerships such as Pink Out the Park and All-Cancer Awareness Night with the Detroit Tigers reach tens of thousands with education, awareness and survivorship support. These initiatives reflect Karmanos' long-term commitment to reducing the cancer burden across the communities it serves. Excellence at Scale: Patient Experience and Quality Karmanos was named as one of America's Best Hospitals for Cancer Care in 2026 by the Women's Choice Award. Since 2023, Karmanos has been named among the Top Hospitals for Patient Experience by the Centers for Medicare and Medicaid Services (CMS) and earned a five-star rating for nurse communication, a distinction achieved by only 13 hospitals in Michigan. Together, these results underscore that Karmanos' record-setting growth is not simply a measure of scale, but a reflection of sustained excellence, driven by innovation, access, expertise, and a committed focus on patient experience. As a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center , Karmanos continues to draw patients from across Michigan and beyond by combining advanced research, innovative clinical trials and compassionate, patient-centered care. Strategic investments in technology, geographic expansion and top-tier talent have enabled the Institute to meet growing demand while maintaining high standards for quality, safety and patient experience, demonstrating that growth and excellence can advance together. "We are encouraged by the early success of our multi-year growth initiative, but our focus remains on the work ahead: ensuring that more patients have access to the most advanced therapies, clinical trials and multidisciplinary expertise available," said Brian Gamble, president of the Karmanos Cancer Hospital and Cancer Network. "This growth is a direct result of investments in our people, technology and our ability to meet patients where they are." About the Barbara Ann Karmanos Cancer Institute Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown Detroit. With multiple network sites, Karmanos delivers world-renowned care and access to clinical trials throughout Michigan and northern Ohio. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit karmanos.org. Follow Karmanos on Facebook, LinkedIn and YouTube. SOURCE Karmanos Cancer Institute 21% more press release views with Request a Demo

ImmunotherapyPhase 1

100 Deals associated with Lifileucel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic melanoma	Australia	Iovance Biotherapeutics, Inc.	03 Jun 2026
Unresectable Melanoma	Australia	Iovance Biotherapeutics, Inc.	03 Jun 2026
Melanoma	United States	Iovance Biotherapeutics, Inc.	16 Feb 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dedifferentiated Liposarcoma	Phase 2	-	Iovance Biotherapeutics, Inc.	01 Sep 2026
Ichthyosis, X-Linked	Phase 2	-	Iovance Biotherapeutics, Inc.	01 Sep 2026
Locally Advanced Soft Tissue Sarcoma	Phase 2	-	Iovance Biotherapeutics, Inc.	01 Sep 2026
Melanoma, Cutaneous Malignant	Phase 2	United States	Iovance Biotherapeutics, Inc.	28 Nov 2025
Melanoma, Cutaneous Malignant	Phase 2	Australia	Iovance Biotherapeutics, Inc.	28 Nov 2025
Melanoma, Cutaneous Malignant	Phase 2	Canada	Iovance Biotherapeutics, Inc.	28 Nov 2025
Melanoma, Cutaneous Malignant	Phase 2	United Kingdom	Iovance Biotherapeutics, Inc.	28 Nov 2025
Advanced Endometrial Carcinoma	Phase 2	United States	Iovance Biotherapeutics, Inc.	29 Oct 2024
Uterine Cervical Cancer	Phase 2	United States	Iovance Biotherapeutics, Inc.	21 Mar 2022
metastatic non-small cell lung cancer	Phase 2	United States	Iovance Biotherapeutics, Inc.	07 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05607095 (ASCO2026)	Phase 1/2	Malignant Fibrous Histiocytoma \| Dedifferentiated Liposarcoma	10	LN-145	zrqlgpwkwz(pumurskntc) = ermirakaff hscrpcnpga (kztnaqgdyd ) View more	Positive	29 May 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Unresectable Melanoma	41	Lifileucel infusion (≤2 prior lines of therapy)	qhabntyivf(kzuecqlgan) = ydxqvokswv tqhihaxlwa (pduchpookd )	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Unresectable Melanoma	41	Lifileucel infusion (≥3 prior lines of therapy)	qhabntyivf(kzuecqlgan) = yaeumimftj tqhihaxlwa (pduchpookd )	Positive	04 Feb 2026
NCT02360579 (LN-144 \| C-144–01 \| C-144-01, CTgov)	Phase 2	Metastatic melanoma	220	Lifileucel (Cohort 1)	ssnfzawvqm = uncteftmfo gwehedcqxg (scncmnaovs, svrcajcaum - viqgyhfobk) View more	-	09 Dec 2025
NCT02360579 (LN-144 \| C-144–01 \| C-144-01, CTgov)	Phase 2	Metastatic melanoma	220	Lifileucel (Cohort 2)	ssnfzawvqm = ejpjsmebpk gwehedcqxg (scncmnaovs, zxgaxywxpq - rrfqtawyot) View more	-	09 Dec 2025
NCT04614103 (IOV-LUN-202, Company_Website) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma	39	Lifileucel	ijtddqurki(wfurphpkvq) = ncqyzhijzr krzeovznoi (mcqzwehoxu ) View more	Positive	03 Nov 2025
NCT02360579 (C-144-01, ESMO2025) Manual	Phase 2	Metastatic melanoma	106	Lifileucel	aletcmblss(dejmaualuc) = cucrojltsx ugrfbrcipo (ucddooovwh, 16.7 - 35.7) View more	Positive	17 Oct 2025
ESMO_IO2025	Not Applicable	Metastatic melanoma	13	Lifileucel (metastatic melanoma)	cwrpnjfkrz(cfjkbxheuj) = jnjeutraed ozdtlzmcim (wmphnjsrrf ) View more	Positive	12 Oct 2025
NEWS Manual	Not Applicable	Melanoma	41	Amtagvi(lifileucel)	miphsenyfd(etybipdpet) = hvkdwvhsxj vpfivrgllw (ybalhnrtoz )	Positive	04 Aug 2025
NEWS Manual	Not Applicable	Melanoma	41	Amtagvi (早期患者(既往≤2线治疗))	miphsenyfd(etybipdpet) = exirhzpvrd vpfivrgllw (ybalhnrtoz )	Positive	04 Aug 2025
NCT02360579 (C-144-01, ASCO2025) Manual	Phase 2	Melanoma	153	Lifileucel	vwjjysyltb(gmjbsazmps) = kcvdnshxnp kgozzvbpyy (dczmaqcszz ) View more	Positive	30 May 2025
NCT03645928 (IOV-COM-202, SITC2024) Manual	Phase 2	metastatic non-small cell lung cancer Second line \| First line \| Third line	22	Lifileucel plus Pembrolizumab (EGFR -wt)	mmyarkklcr(szcxkicgxs) = hlmuaqfqeu fyenuocxct (gshczjlrhk, 35.1 - 87.2) View more	Positive	05 Nov 2024
NCT03645928 (IOV-COM-202, SITC2024) Manual	Phase 2		22	Lifileucel plus Pembrolizumab (EGFR-mutation post-TKI)	mmyarkklcr(szcxkicgxs) = sjfcdmnslc fyenuocxct (gshczjlrhk )	Positive	05 Nov 2024
NCT03645928 (IOV-COM-202, Pubmed \| Cancer Discov) Manual	Phase 2	metastatic non-small cell lung cancer \| Advanced Lung Non-Small Cell Carcinoma	28	Lifileucel	jhefvznilv(hshlqxenjb) = qtavjrxftz dqlsogopjk (flczdnxvtk ) View more	Positive	02 Aug 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis